Exhibit 10.1

Certain confidential information contained in this document, marked by brackets and asterisk ([***]), has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because the Company customarily and actually treats such information as private or confidential and the omitted information is not material.

SHARE PURCHASE AGREEMENT

THIS SHARE PURCHASE AGREEMENT (this “Agreement”) made effective as of August 29, 2026 (the “Effective Date”), by and among CollPlant Biotechnologies Ltd., a company incorporated under the laws of the State of Israel, Registration No. 520039785 (the “Buyer”), LightSolver Ltd., a company incorporated under the laws of the State of Israel, Registration No. 516117439 (the “Company”), and the shareholders of the Company listed on Exhibit A hereto (collectively, the “Current Shareholders”), each of whom is executing this Agreement through a Joinder or by way of a proxy to Ruti Ben Shlomi (the “Proxy Holder”) pursuant to a Seller Proxy (as defined herein). The Former SAFE Holders required to become a party hereto pursuant to Section 2.3.3, shall become a party to this Agreement upon execution of a Joinder (whether directly or pursuant to a Seller Proxy) in accordance with Section 3.5.

The Buyer, the Company and the Current Shareholders are referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, the Proxy Holder holds valid and irrevocable Seller Proxies from each of the Sellers (other than Sellers executing this Agreement or a Joinder directly), authorizing the Proxy Holder to execute and deliver this Agreement, the Joinder and all other Transaction Documents on behalf of such Sellers, and to consummate the Transactions on their behalf;

WHEREAS, the Buyer desires to acquire one hundred percent (100%) of the issued and outstanding share capital of the Company on a fully-diluted basis, including all Shares, options, warrants, convertible securities and other rights to acquire share capital of the Company¹ (the “Acquisition”), on the terms and subject to the conditions set forth in this Agreement and to the Schedule of Exceptions of Section 6;

WHEREAS, the Company is engaged in the business of developing and commercializing advanced, quantum-inspired computing hardware, specifically proprietary, room-temperature laser-based processing units (LPUs), designed to solve complex, multi-variable NP-hard optimization problems and provide high-performance computational solutions for enterprise applications across data-intensive industries such as logistics, finance, aerospace, and energy (the “Business”);

WHEREAS, the aggregate consideration to be paid by the Buyer to the Current Shareholders in connection with the Acquisition shall consist of (i) ordinary shares of the Buyer to be issued at the Closing (the “Closing Shares”), (ii) pre-funded warrants to purchase ordinary shares of the Buyer (the “Pre-Funded Warrants”), and (iii) certain milestone-based warrants to purchase ordinary shares of the Buyer, exercisable upon the achievement of certain milestones as further detailed below (the “Milestone Warrants” and, together with the Closing Shares and the Pre-Funded Warrants, the “Consideration Securities”), all as more fully described in this Agreement;

WHEREAS, following the consummation of the Acquisition, the Company will become a wholly-owned subsidiary of the Buyer, and the Buyer intends to integrate the Company’s Business with its own operations in furtherance of the Buyer’s strategic objectives;

WHEREAS, the board of directors of each of the Buyer and the Company has (i) determined that the Acquisition is fair to, and in the best interests of, such party and its respective shareholders, and (ii) approved this Agreement and the transactions contemplated hereby, including the Acquisition, in accordance with applicable law and the articles of association of such party;

WHEREAS, the Parties intend that the execution of this Agreement and the consummation of the Acquisition shall occur simultaneously (the “Sign-and-Close”), such that the Closing (as defined herein) shall take place concurrently with the execution hereof, and no separate closing condition period shall apply, subject only to the satisfaction or waiver of the conditions set forth in Section 3 of this Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties and agreements set forth herein, the Parties hereby agree as follows:

“102 Options” means Options granted under the Company Plan which are subject to tax pursuant to Section 102 of the Ordinance and held by the 102 Trustee.

“102 Trustee” means the trustee appointed by the Company and approved by the ITA in accordance with Section 102 of the Ordinance, and any regulations promulgated thereunder, for the purpose of holding and administering Options granted under the Company Plan pursuant to Section 102 of the Ordinance.

“3(i) Options” means Options granted under the Company Plan which are subject to tax pursuant to Section 3(i) of the Ordinance.

“Acquired Shares” means all Company Shares representing 100% of the issued and outstanding share capital of the Company on a Fully Diluted Basis, subject to the Schedule of Exceptions of Section 6.

“Affiliate” means with respect to any person or entity, any person or entity directly or indirectly, controlling such person, controlled by or under common control with such person or entity, without limitation, any general partner, managing member, officer or director of that person or entity, or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with that person or entity. For this purpose: “Control” shall mean: (i) the ability to direct, or cause the direction of, the management and policies of the relevant person, whether through the ownership of voting securities, by contract or otherwise, and whether directly or indirectly, or (ii) the beneficial ownership (directly or indirectly, including through one or more intermediaries) of 50% or more of the ownership interests in such person, including the issued and outstanding share capital, voting rights or other ownership interests or the right to appoint the majority of the directors (or the equivalent thereof) in such person.

“Agreed Diluted Basis” means the total number of the Buyer’s issued and outstanding Ordinary Shares, together with all securities convertible into, exercisable for or exchangeable for Buyer Ordinary Shares, in each case on a fully diluted basis as of the Closing Date, excluding any outstanding warrants and any options granted under the Buyer’s Plan, that are out-of-the-money as of the Closing Date, all as set forth on the Capitalization Table attached as Exhibit A.

“Agreement” means this Share Purchase Agreement including all exhibits and schedules attached hereto, as the same may be amended, modified or supplemented from time to time in accordance with its terms.

“Anti-Corruption Law” means any Applicable Law relating to bribery, corruption or similar activities, including without limitation the Israeli Penal Law 5737-1977, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the UK Bribery Act 2010.

“Applicable Law” or “Law” means all laws, regulations, directives, statutes, subordinate legislation, all judgments, orders, notices, instructions, decisions and awards of any court or competent authority or tribunal exercising statutory or delegated powers issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity and all statutory guidance and policy notes having a force of law, in each case to the extent applicable to the parties or any of them, or as the context requires.

“Balance Sheet” means the draft, unaudited balance sheet of the Company, a copy of which is attached to Schedule 6.13 of the Schedule of Exceptions.

“Bring-Along Provision” means Article 20.5 of the Company’s current articles of association (the “Current Articles”).

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States, a legal holiday in the State of Israel or any day on which banking institutions in the State of New York or in the State of Israel are authorized or required by law or other governmental action to close; provided, however, that, for calculating Business Days with respect to any action to be taken by the Company hereunder, Friday after 1:00 p.m. (Tel Aviv time) shall not be considered a Business Day.

“Buyer Ordinary Shares” means ordinary shares, of the Buyer, no Par Value.

“Buyer Schedule of Exceptions” means the disclosure schedules delivered by the Buyer to the Company concurrently with the execution of this Agreement and attached hereto as Schedule 7.

“Cause” means, with respect to a Key Person: (a) such Key Person’s willful misconduct or gross negligence in the performance of his or her duties; (b) such Key Person’s commission of fraud, embezzlement, dishonesty or other willful misconduct that results in material harm to the Company or the Buyer; (c) such Key Person’s conviction of, or plea of guilty or nolo contendere to, a felony or a crime involving moral turpitude; (d) such Key Person’s material violation of applicable law, regulation, or stock exchange rule, to the extent such violation causes material harm to the Company or the Buyer; or (e) such Key Person’s habitual or repeated neglect of duties, continued failure or refusal to perform his or her duties in any material respect, or abandonment of employment, which (if curable) is not cured within thirty (30) days after written notice thereof.

“Closing” has the meaning set forth in Section 3.1.

“Closing Date” means the date of execution of this Agreement.

“Closing Shares” means 3,734,476 newly issued Buyer Ordinary Shares, representing 19.75% of the issued and outstanding Buyer Ordinary Shares immediately prior to the execution of this Agreement, to be issued to the Sellers in accordance with Section 2.2.1 in such number and allocated among them as set forth in Exhibit A.

“Companies Law” means the Israeli Companies Law 5759-1999 and any regulations promulgated thereunder.

“Company IP” means all Intellectual Property owned by, or exclusively licensed to, the Company or used or held for use in the conduct of the Company’s business as currently conducted.

“Company Plan” means the Company’s 2020 Share Option Plan.

“Company Shares” means all issued and outstanding shares of any class of the Company, as set forth in Schedule 6.2 of the Schedule of Exceptions.

“Confidential Information” means any and all information, data, documents, agreements, files and other materials which relate to the business, assets, financial position, customers, operations, or affairs of a Party which are not publicly known, whether or not specifically identified as confidential, including without limitation trade secrets, Inventions, business plans, financial data, customer lists, supplier information, marketing strategies, proprietary software, technical data, product designs, and any other information of a confidential or proprietary nature.

“Current Shareholders” means all of the shareholders of the Company on the date hereof, as set forth in Exhibit A attached hereto.

“Data Protection Law” means all Applicable Laws in connection with data protection and privacy protection which apply to the Company, including without limitation the European Regulation (EU) 2016/679 (the General Data Protection Regulation) and the Israel Privacy Protection Law 5741-1981 and the rules and regulations promulgated thereunder.

“Disclosed” means fully, fairly and specifically disclosed in the Schedule of Exceptions.

“Encumbrances” means any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, option, right of first refusal, right of first negotiation, right of first notice, preemptive right, title reversion agreement, easement, servitude, proxy, voting trust or agreement, transfer restriction under any shareholder or similar agreement, except for any encumbrance or other restriction imposed directly pursuant to this Agreement or under any Applicable Law.

“Equity Blocker” has the meaning set forth in Section 2.4.

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“Fully Diluted Basis” means with respect to any person, all issued and outstanding share capital of any class, warrants, options, convertible loans, rights and convertible securities of such person, all on an as-if exercised and as-converted basis (including all rights and promises of any kind that could directly or indirectly result in any right to receive or purchase any of the foregoing).

“Former Optionholder” means any Person who held Options immediately prior to Closing and whose Options will be exercised and whose resulting Company Shares are sold to the Buyer in consideration for Buyer Ordinary Shares in accordance with Section 2.3.3.

“Former SAFE Holder” means any Person who held a SAFE immediately prior to Closing and whose SAFE is converted and whose resulting Company Shares are sold to the Buyer in consideration for Buyer Ordinary Shares in accordance with Section 2.3.4.

“Founder” means Ruti Ben-Shlomi, I.D. No. [***].

“Seller Proxy” means an irrevocable proxy and power of attorney, substantially in the form attached hereto as Exhibit L, granted by each of the Sellers (other than Sellers executing this Agreement or a Joinder directly) to the Founder, authorizing the Proxy Holder to: (a) execute and deliver this Agreement, the Joinder and all other Transaction Documents on behalf of such Seller; (b) execute share transfer deeds transferring such Seller’s Company Shares (including Company Shares issued upon conversion of a SAFE immediately prior to Closing) to the Buyer; (c) make and deliver all representations, warranties and covenants on behalf of such Seller as contemplated by this Agreement and the Joinder; and (d) take all other actions necessary or desirable to consummate the Transactions on behalf of such Seller. Each Seller Proxy shall be coupled with an interest and shall be irrevocable.

“Seller” means any one of the Sellers. “Sellers” means, collectively, the Current Shareholders and the Former SAFE Holders, other than as are listed in the Company Schedule of Exceptions.

“Fundamental Representations” means the representations and warranties set forth in Sections 6.1 (Organization; Good Standing), 6.2 (Share Capital), 6.3 (Authorization; Approvals), 6.6 (Insolvency) and 6.9 (Intellectual Property).

“Good Reason” means, with respect to a Key Person: (a) a material reduction in such Key Person’s compensation or benefits (other than in connection with a general reduction applicable to all senior executives of the Company or the Buyer, as applicable); (b) a material diminution in such Key Person’s duties or responsibilities (provided that changes in title, reporting lines, or organizational structure alone shall not constitute Good Reason so long as the Key Person retains substantially similar duties and responsibilities in the aggregate); or (c) a requirement that such Key Person relocate his or her principal place of employment more than fifty (50) kilometers from its current location without such Key Person’s prior written consent. Notwithstanding the foregoing, no event shall constitute Good Reason unless (x) the Key Person provides written notice to the Company or the Buyer, as applicable, within thirty (30) days after the occurrence thereof, (y) the Company or the Buyer, as applicable, fails to cure such event within thirty (30) days following its receipt of such notice, and (z) the Key Person terminates his or her engagement within thirty (30) days after the expiration of such cure period.

“Governmental Entity” means any government or governmental or regulatory body thereof, whether federal, state, local or foreign, or any agency, instrumentality or authority thereof, or any competent court or arbitral body, exercising executive, legislative, judicial, regulatory or administrative functions, including but not limited to the SEC, Nasdaq, the ITA, and the Israeli Registrar of Companies.

“Indemnification Agreements” means the indemnification agreements to be executed by (i) the directors who will be appointed to the Buyer’s board of directors, and (ii) the directors of the Company immediately after Closing, effective as of Closing, in the forms attached hereto as Exhibits J1 and J2, respectively.

“Intellectual Property” or “Intellectual Property Rights” means patents, utility models, trademarks, service marks, trade and business names, registered designs, design rights, copyright rights, trade secrets, confidential information of all kinds and other similar proprietary rights which may subsist in any part of the world and whether registered or not, including, where such rights are obtained or enhanced by registration, any registration of such rights and rights to apply for such registrations.

“Inventions” means any patent applications, patents, know-how, technical information, work product, designs, ideas, concepts, information, materials, processes, data, programs, improvements, innovations, discoveries, developments, artwork, works of authorship, concepts, drawings, algorithms, techniques, methods, systems, processes, compositions of matter, computer software programs, databases and mask works, formulae, other copyrightable works, and techniques, whether or not patentable, copyrightable or protectable as trade secrets, irrespective of whether registered as a patent, copyright, trademark or in another form.

“ITA” means the Israel Tax Authority.

“Key Persons” means each of the following individuals: (1) Ruti Ben-Shlomi, and (2) Chene Tradonsky.

“Knowledge of the Company” or “Company’s Knowledge” means any fact, thing or matter actually known by any of the following individuals: (i) any director of the Company, (ii) any officer of the Company (including the chief executive officer, chief financial officer, chief technology officer, chief operating officer, vice president of research and development, and general counsel or legal director, if any), or (iii) any Key Person.

“Knowledge of the Buyer” or “Buyer’s Knowledge means any fact, thing or matter actually known by any of the following individuals: (i) any director of the Buyer or (ii) any officer of the Buyer (including the chief executive officer, deputy CEO & chief financial officer, vice president of operating officer, vice president of research and development, vice president of QA & QC and the general counsel, if any.

“Subsidiary Assets” means CollPlant Ltd. who owns all assets, Intellectual Property, contracts and business relating to the Buyer’s biotechnology business conducted prior to the Closing.

“Material Adverse Effect” means any event, circumstance, change, effect, development or condition that, individually or in the aggregate, (a) is or would reasonably be expected to be materially adverse to the business, assets (including intangible assets), liabilities, condition (financial or otherwise), properties, operations or results of operations of a Party, or (b) would reasonably be expected to prevent or materially impair or delay the ability of a Party to consummate the Transactions; provided, however, that none of the following shall be deemed to constitute, and none of the following shall be taken into account in determining whether there has been or would reasonably be expected to be, a Material Adverse Effect: (i) changes in general economic, business, financial, credit, currency or capital market conditions; (ii) changes in conditions generally affecting the industries or markets in which the relevant Party operates; (iii) any act of war (whether or not declared), armed hostilities, sabotage, terrorism, or any escalation or worsening thereof; (iv) any earthquake, hurricane, tsunami, tornado, flood, mudslide, wildfire, pandemic, epidemic or other natural or man-made disaster or act of God; (v) changes in Applicable Laws or regulations, or the interpretation or enforcement thereof, after the date hereof; (vi) changes in GAAP, IFRS or other applicable accounting standards, or the interpretation thereof, after the date hereof; (vii) any failure by a Party to meet any internal or published projections, forecasts, estimates or predictions (provided that the underlying causes of such failure may be considered in determining whether a Material Adverse Effect has occurred); (viii) the announcement, pendency or consummation of the Transactions or the identity of the Buyer as the acquiror (including any loss of, or adverse change in, the relationship of the Company with any customers, suppliers, employees, financing sources or other business partners resulting therefrom); or (ix) any action taken or omitted to be taken by a Party at the written request of, or with the prior written consent of, the other Party.

“Milestone Warrants” means pre-funded warrants to purchase Buyer Ordinary Shares, subject to the Equity Blocker, with an exercise price of USD 0.00001 per share, consisting of (i) the warrants issuable upon achievement of Milestone 1 (the “Milestone 1 Warrants”), (ii) the warrants issuable upon achievement of Milestone 2 (the “Milestone 2 Warrants”), and (iii) the warrants issuable upon achievement of Milestone 3 (the “Milestone 3 Warrants”), in each case allocated among the Sellers on a Pro Rata Basis and in accordance with the numbers of such warrants as are set forth in Exhibit A and in the form attached hereto as Exhibit C.

“Milestone 1” means the occurrence of the event(s) set forth as Milestone 1 on Exhibit M hereto.

“Milestone 2” means the occurrence of the event(s) set forth as Milestone 2 on Exhibit Mhereto.

“Milestone 3” means the occurrence of the event(s) set forth as Milestone 3 on Exhibit M hereto.

“Nasdaq” means The Nasdaq Stock Market LLC or any successor thereto.

“Net Cash” means US$5,000,000, to be transferred by Buyer to the account of the Company ( details of which have been provided in writing by the Company to Buyer) at Closing to be used by the Company for its operations in achieving the Milestones.

“Options” means, collectively, the 102 Options and the 3(i) Options.

“Ordinance” means the Israeli Income Tax Ordinance [New Version] 5721-1961 and all the regulations, rules and orders promulgated thereunder.

“Permits” means any approvals, authorizations, consents, licenses, permits or certificates of a Governmental Entity.

“Permitted Encumbrances” as set forth in Schedule 1.1(d).

“Person” or “person” means (i) any individual, firm, company, limited liability company, joint stock corporation or other company, governmental body, joint venture, association, trust or partnership, works council, or any other entity of any kind (whether or not having a separate legal personality), and (ii) a reference to that person’s legal personal representatives and successors.

“Buyer Plan” means the Buyer’s 2024 Share Award Plan, as approved by the Buyer’s Board of Directors on April 3, 2024, and the Buyer’s Share Ownership and Option Plan (2010), as extended by the Buyer’s Board of Directors on March 26, 2020.

“Pre-Funded Warrants” means warrants to purchase Buyer Ordinary Shares in such number as is set forth in Exhibit A hereto, subject to the Equity Blocker, with an exercise price of USD 0.00001 per share, allocated among the Sellers as set forth in Exhibit A, in the form attached hereto as Exhibit D.

“Per Share Consideration” means the implied value per Company Share, calculated by dividing the aggregate Consideration Securities by the total number of Company Shares on a Fully Diluted Basis immediately prior to Closing.

“Pro Rata Basis” or “Pro Rata Share” means, with respect to each Current Shareholder, the proportion that such Current Shareholder’s Company Shares (on an as-converted basis) bears to the total issued and outstanding Company Shares (on a Fully Diluted Basis) immediately prior to the Closing, as set forth in Exhibit A.

“Requisite Shareholder Approval” means the approval by shareholders holding at least 51% of the issued and outstanding share capital of the Company, according to their voting rights as set forth in the Current Articles, of this Agreement and the Transactions, and (b) requisite percentage required for the adoption of the Amended and Restated Articles in replacement of the Current Articles, effective as of the Closing.

“ROC” means the Israeli Registrar of Companies.

“Rule 144” means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.

“SAFE” means any Simple Agreement for Future Equity or similar convertible instrument issued by the Company entitling the holder thereof to receive Company Shares upon conversion in accordance with the terms thereof, as set forth in Schedule 1.1(e) , subject to the Schedule of Exceptions of Section 6.

“Schedule of Exceptions” means the disclosure schedules delivered by the Company and the Current Shareholders to the Buyer concurrently with the execution of this Agreement attached hereto as Schedule 6.

“SEC” means the U.S. Securities and Exchange Commission.

“SEC Reports” means all reports, schedules, forms, statements and other documents required to be filed or furnished by the Buyer under the Securities Act and the Exchange Act, including pursuant to Sections 13(a), 14(a) or 15(d) thereof, for the two (2) years preceding the date hereof, including any amendments or supplements thereto.

“Securities” means, collectively, the Closing Shares, the Pre-Funded Warrants, the Milestone Warrants, and the Warrant Shares.

“Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Securities Issuance” means the issuance by the Buyer to the Sellers of the Consideration at the Closing.

“Sellers’ Representative” means Ruti Ben-Shlomi, or such successor as may be designated in accordance with Section 12.12.

“Subsidiary” means, with respect to any Person, any other Person of which 50% or more of the outstanding voting securities or other ownership interests are owned, directly or indirectly, by such first Person.

“Tax” or “Taxation” means all forms of taxation, levy, duty, charge, impost or withholding of any nature whatsoever (including any related fine, penalty, surcharge, interest or addition to tax) imposed, collected or assessed by, or payable to, any Governmental Entity, whether of Israel, the United States or any other jurisdiction.

“Tax Ruling” means the ruling or determination from the ITA dated August 10, 2026, in form and substance reasonably satisfactory to the Buyer and the Sellers’ Representative, confirming the Section 103K tax treatment of the Transactions (which ruling may be subject to customary conditions regularly associated with such rulings).

“Trading Day” means a day on which Nasdaq is open for trading.

“Trading Market” means any of the following markets or exchanges on which the Buyer Ordinary Shares are listed or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, or any successor thereto.

“Transaction Agreements” means this Agreement, and each other agreement, document and instrument executed and delivered in connection with the Transactions.

“Transactions” means the transactions contemplated by this Agreement and the Transaction Agreements.

“Trustee” means the 102 Trustee.

“US GAAP” means United States generally accepted accounting principles, consistently applied.

“Warrant Shares” means the Buyer Ordinary Shares issuable upon exercise of the Pre-Funded Warrants and the Milestone Warrants.

Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document and for the avoidance of any doubt, in no event shall the Buyer issue to any Seller, holder of Rollover Options or any other holder of securities of the Company any Buyer Ordinary Shares to the extent such issuance would exceed any applicable threshold under Nasdaq Listing Rule 5635 unless and until the Company obtains shareholder approval required by Nasdaq Rule 5635.

Each certificate representing Consideration Securities shall be imprinted with a legend substantially similar to the following (in addition to any legend required under applicable securities laws or as provided elsewhere in this Agreement):

“THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED PURSUANT TO REGULATION D/S OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE THEREWITH, PURSUANT TO A REGISTRATION UNDER THE ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. IN ADDITION NO HEDGING TRANSACTION MAY BE CONDUCTED WITH RESPECT TO THESE SECURITIES UNLESS SUCH TRANSACTIONS ARE IN COMPLIANCE WITH THE ACT.”

In addition, each certificate representing Consideration Securities may contain any legend required by the securities laws of any jurisdiction to the extent such laws are applicable to the sale and issuance of such Securities.

Each Current Shareholder hereby represents and warrants to the Buyer, severally and not jointly, as of the date hereof, as follows:

The Company hereby represents and warrants to the Buyer, as of the date hereof, subject to the disclosures set forth in the Schedule of Exceptions attached hereto as Schedule 6 (“Schedule of Exceptions”) (each of which shall qualify only the specifically identified Section of this Agreement to which such disclosure expressly relates), as follows:

The Buyer hereby represents and warrants to the Company and the Current Shareholders, as of the date hereof, subject to the disclosures set forth in the Buyer Schedule of Exceptions attached hereto as Schedule 7 (“Buyer Schedule of Exceptions”), as follows:

If to the Buyer:

CollPlant Biotechnologies Ltd.

4 Oppenheimer Street, Rehovot, 7670104 Israel

Attention:

Eran Rotem, Deputy CEO and CFO

Email: eran@collplant.com; and

Bar Abelis, VP Legal

Email: bara@collplant.com

With a copy (which shall not constitute notice) to:

Amit Pollak Matalon & Co.

Adress: APM House, 18 Raoul Wallenberg St.,

Building D, 5th floor, Ramat Hachayal,

Tel Aviv, 6971915, Israel

Attention: Ronen Kantor, Adv.

Telephone No.: +972-3-5689000

E-mail: rkantor@apm.law

If to the Company:

LightSolver Ltd.

94 Yigal Alon Street, 2nd Alon Tower, 14 Floor, Tel Aviv-Jaffa, Israel

Attention: Ruti Ben Shlomi

Email: ruti@lightsolver.com

With a copy (which shall not constitute notice) to:

Pearl Cohen Zedek Latzer Baratz.

Adress: Azrieli Sarona Tower- 53rd floor, 121 Menachem Begin Rd. Tel-Aviv, 6701203, Israe

Attention: Oded Kadosh, Adv.

Telephone No.: +972-3-3039000

E-mail: OdedK@pearlcohen.com

If to the Sellers’ Representative:

Ruti Ben Shlomi

29 Hadar Steet Cesaria, Israel

Email: ruti@lightsolver.com

IN WITNESS WHEREOF, the Parties have executed this Share Purchase Agreement as of the date first written above.

SELLERS:

Each Seller shall execute this Agreement and the Joinder by signing below or through the Proxy Holder pursuant to a Seller Proxy, or as set forth in the Joinder and Shareholder Acceptance attached as Exhibit B hereto.

SELLERS’ REPRESENTATIVE: